**Supplemental table 2. Association between *TAZ or YAP* mRNA expression and patient’s characteristics in hepatocellular carcinoma**

1. ***TAZ* mRNA**

Clinical factors TAZ low (n = 78) TAZ high (n = 32) p-value

Age, yr 64.7 ± 8.9 67.5 ± 10 0.151

Male, n (%) 66 (84.6%) 27 (84.3%) 0.975

Etiology

NonBnonC / HBV / HCV / B and C 21 / 19 / 35 / 3 9 / 11 / 11 / 1 0.688

Tumor size, mm 44 ± 28 58 ± 37 0.035

Solitary tumor, n (%) 1.4 ± 1.0 1.8 ± 0.8 0.075

AFP 3960 ± 26332 2170 ± 5312 0.709

PIVKA-II 7344 ± 31607 5013 ± 10406 0.685

*t*-test or Pearson's chi-squared test (χ2) was used. AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence/antagonist-II.

1. ***YAP* mRNA**

Clinical factors YAP low (n = 71) YAP high (n = 24) p-value

Age, yr 66.4 ± 7.7 64.7 ± 13.6 0.434

Male, n (%) 60 (84.5%) 20 (83.3%) 0.892

Etiology

NonBnonC / HBV / HCV / B and C 19 / 19 / 30 / 3 8 / 10 / 6 / 0 0.261

Tumor size, mm 48 ± 31 58 ± 36 0.159

Solitary tumor, n (%) 1.4 ± 0.8 1.6 ± 0.9 0.286

AFP 4306 ± 27732 2282 ± 5684 0.724

PIVKA-II 5940 ± 25022 12164 ± 38860 0.368

*t*-test or Pearson's chi-squared test (χ2) was used. AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence/antagonist-II.